Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 2b7f6fabon Jul 26, 2022 12:50am
293 Views
Post# 34850078

RE:RE:RE:RE:RE:RE:What happened to radachlorin pdt for NMIBC?

RE:RE:RE:RE:RE:RE:What happened to radachlorin pdt for NMIBC?I appreciate all your contributions SF.  However UHN undertreating the first 12 patients of PH2 has set this company back at least 2 years and that was after they successfully applied the so called optimized procedure to patients 4~6 in PH1.  After that tremendous FU I would never recommend anyone get treated at UHN PMCC..  I don't have years and years to piss away unlike the rest of the board members. (sarcasm)

ScienceFirst wrote: We have to give credit to TLT that does everything by the book and never cut corners when it comes to what the FDA/HC/EU require in terms of papers and rigorous standards.

By teaming up with UHN and PMCC, we were sure to never have a flawed study.  TOOKAD and Radachlorin seem to have taken a shorted route that lead them nowhere.  That's usually what happen when you cut corners.

I remember some clown investors back in 2015 asking TLT to do it's Ph. 1b in an airplane or on an ship in international waters so it could get around the rigorous FDA/HC requirements!  It's unbelievable that clowns we have on internet, thinking they know things should be done!  lollll


<< Previous
Bullboard Posts
Next >>